Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 732-733

  Gromke, T ^a   Elmaagacli, A H ^a   Ditschkowski, M ^a   Hegerfeldt, Y ^a   Koldehoff, M ^a   Hlinka, M ^a   Ottinger, H ^a   Trenschel, R ^a   Beelen, D W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; HISTAMINE RECEPTOR 1/2 ANTAGONIST; IMATINIB; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TREOSULFAN; TRYPTASE; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ASSOCIATED CLONAL HEMATOLOGICAL NON MAST CELL LINEAGE DISEASE; BONE MARROW; CASE REPORT; CELL THERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG DOSE REDUCTION; ENZYME BLOOD LEVEL; EXTENSIVE CHRONIC MUCOCUTANEOUS GRAFT VERSUS HOST DISEASE; FLUSHING; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS MAST CELL EFFECT; HEMATOLOGIC DISEASE; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LETTER; LIVER FUNCTION; MALE; MEDIATOR RELEASE; MYELOABLATIVE CONDITIONING; PANCYTOPENIA; PRIORITY JOURNAL; REMISSION; SYSTEMIC MASTOCYTOSIS;

CELL LINEAGE; GRAFT VS HOST REACTION; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84877669323     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.198     Document Type: Letter

References (10)

1. Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006; 37: 353-358.
2. Rønnov-Jessen D, Løvgreen Nielsen P, Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 1991; 8: 413-415.
3. Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A et al. Advanced mast cell disease: an Italian hematological multicenter experience. Int J Hematol 2008; 88: 483-488.
4. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment in options and proposed response criteria. Leuk Res 2003; 27: 635-641(review).
5. Chong G, Byrnes G, Szer J, Grigg A. Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000; 26: 1011-1015 (review).
6. Ludolph-Hauser D, Ruëff F, Sommerhoff CP, Przybilla B. Tryptase a marker for the activation and localization of mast cells. Hautarzt 1999; 50: 556-561(review; German).
7. Zettinig G, Becherer A, Szabo M, Uffmann M, Dudczak R, Valent P et al. FDG positron emission tomography in patients with systemic mastocytosis. AJR Am J Roentgenol 2002; 179: 1235-1237.
8. LeBlanc AK, Jakoby BW, Townsend DW, Daniel GB. 18FDG-PET imaging in canine lymphoma and cutaneous mast cell tumor. Vet Radiol Ultrasound 2009; 50: 215-223.
9. Kurosawa M, Amano H, Kanbe N, Igarashi Y, Nagata H, Yamashita T et al. Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis. J Allergy Clin Immunol 1999; 1003(Part 2): 412-420.
10. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000; 14: 659-687 (vii; review).